Business Context and Reporting Period
This Form 8-K filing by DanDrit Biotech USA, Inc. (referred to in metadata as Lunai Bioworks Inc.) reports on events occurring through October 10, 2014, with the report filed on October 15, 2014. The filing details the completion of closings for a registered direct placement of common stock.
Key Financial Metrics
- Gross Proceeds: $2,226,500 raised from the sale of 445,300 shares.
- Offering Price: $5.00 per share.
- Transaction Costs: $7,250 paid to the placement agent as accountable expense reimbursement.
- Debt and Liquidity: The filing text does not provide specific values for total debt, cash flow, or liquidity positions outside of the proceeds from this specific offering.
- Profit and Margins: The filing text does not provide revenue, profit, or margin data.
Material Changes
The primary material change is the successful completion of a portion of a "best efforts" public offering. The company sold 445,300 shares, which is a fraction of the total 2,400,000 shares authorized in the original Registration Statement filed in February 2014. Additionally, the closing date for the offering was extended by 30 days to November 13, 2014.
Guidance, Outlook, and Risks
Use of Proceeds: The company intends to utilize the gross proceeds in accordance with the "Use of Proceeds" section described in the original Registration Statement (File No. 333-193965).
Outlook: The extension of the offering deadline to November 13, 2014, indicates the company intends to continue selling shares up to the maximum authorized amount.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard terms of the placement agency agreement.
Investor Verification Checklist
- Verify the specific "Use of Proceeds" detailed in the Registration Statement (File No. 333-193965) to understand capital allocation.
- Confirm the total number of shares sold as of the November 13, 2014, extended deadline.
- Review the full Placement Agency Agreement (Exhibit 1.1) for additional fees or obligations not detailed in this summary.
- Check subsequent filings for the final closing results of the offering.